More than just a DNA repair deficiency syndrome – impaired acetylation in Cockayne syndrome B

By studying the skin phenotype of the hereditary disease Cockayne syndrome researchers at the IUF and HHU Düsseldorf have found a mechanism which can prevent the loss of subcutaneous fat, i.e. one of the cardinal symptoms of Cockayne syndrome. This study was now published in “Science Translational Medicine”.

Düsseldorf, 30/08/2018. The Cockayne syndrome is a very rare hereditary disease, which can lead among others to dwarfism, neurological impairment, premature aging and a shortened life span. Skin symptoms include a striking sensitivity to UV rays and a dramatic loss of subcutaneous fat. The disease is caused in 80 % of the cases by a mutation in the CSB gene. There is no curative treatment. The CSB protein is well known for its role in DNA repair and the Cockayne syndrome therefore usually described as a DNA repair deficiency syndrome. This view, however, does not explain the diverse clinical phenotype of the patients and hence, the CSB protein most likely serves important biological functions beyond DNA repair.

A study of the IUF – Leibniz Research Institute for Environmental Medicine and the Heinrich Heine University Düsseldorf (HHU), Germany, now shows for the first time that the CSB protein is not only present in the nucleus but also at the centrosome of the cell where it enhances acetylation (a certain modification) of α-Tubulin (a protein which forms routes of transportation in the cell) and thereby regulates autophagy (the degradation of cellular material in the cell fluid). If the protein is not able to fulfill this task, an imbalance in protein acetylation occurs. Administration of the histone deacetylase inhibitor SAHA, which inhibits a certain protein family in reversing acetylation, was able to restore this balance. Of note, the loss of subcutaneous fat, i.e. a hallmark of Cockayne syndrome B, could also be restored by SAHA in the mouse model. These results, which have been generated across several species including nematodes, mice and human skin cells, were now published in “Science Translational Medicine”. Future studies will assess if the HDAC inhibitor SAHA, which is a FDA approved drug for treating certain forms of cutaneous T cell lymphoma, is also suitable for the treatment of patients with Cockayne syndrome.

“More and more biological functions beyond DNA repair are being discovered for proteins, which were originally described as DNA repair enzymes. Examples are the CSB protein but also the XPA protein which causes a very severe subtype of Xeroderma pigmentosum”, says Prof. Jean Krutmann, director of the IUF. “This paradigm shift might allow us to identify new strategies for the treatment of these incurable diseases”.

The investigations with the nematodes were conducted by a liaison group between the IUF and the Central Institute of Clinical Chemistry and Laboratory Medicine of the Heinrich Heine University in Düsseldorf, Germany, which is led by Dr. Natascia Ventura.

479 words, 3032 characters

Source
Majora M, Sondenheimer K, Knechten M, Uthe I, Esser C, Schiavi A, Ventura N, Krutmann J: HDAC inhibition improves autophagic and lysosomal function to prevent loss of subcutaneous fat in a mouse model of Cockayne syndrome. Sci Transl Med 10: eaam7510, 2018. doi: 10.1126/scitranslmed.aam7510

Link: www.doi.org/10.1126/scitranslmed.aam7510

More information, including a copy of the paper, can be found online at the Science Translational Medicine press package at www.eurekalert.org/jrnls/scitransmed. You will need your user ID and password to access this information.

About the IUF
The IUF – Leibniz Research Institute for Environmental Medicine investigates the molecular mechanisms through which particles, radiation and environmental chemicals harm human health. The main working areas are environmentally induced aging of the cardiopulmonary system and the skin as well as disturbances of the nervous and immune system. Through development of novel model systems the IUF contributes to the improvement of risk assessment and the identification of novel strategies for the prevention / therapy of environmentally induced health damage.

More information: www.iuf-duesseldorf.com.

The IUF is part of the Leibniz Association: www.leibniz-gemeinschaft.de/en/home.

Contact
Christiane Klasen, Personal Assistant to the institute’s Director
IUF – Leibniz Research Institute for Environmental Medicine
Auf’m Hennekamp 50
40225 Düsseldorf
Germany
Email: Christiane.Klasen@IUF-Duesseldorf.de
Phone: +49 (0)211 3389 216

Go back